Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIN FORSTER

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1972894376
CMS profile
1382219
Location
CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$164,450.85

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $75,923.57 61
Janssen Biotech, Inc. $58,374.23 54
Janssen Scientific Affairs, LLC $16,607.90 11
PFIZER INC. $6,776.80 3
Takeda Pharmaceuticals U.S.A., Inc. $6,653.68 8
Lilly USA, LLC $114.67 2

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIN FORSTER

NPI 1972894376 · CMS profile ID 1382219

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972894376?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIN FORSTER, NPI 1972894376, CMS profile ID 1382219. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972894376?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ERIN FORSTER, NPI 1972894376, CMS profile ID 1382219. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972894376?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ERIN FORSTER, NPI 1972894376, CMS profile ID 1382219, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1972894376?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $164,450.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–139 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $451.8805/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104185704 CMS
ABBVIE INC. $158.2704/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104185698 CMS
ABBVIE INC. $97.8804/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744241 CMS
ABBVIE INC. $1,051.2704/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104185696 CMS
ABBVIE INC. $12.6804/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744239 CMS
Janssen Biotech, Inc. $750.0004/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078626613 CMS
PFIZER INC. $32.7004/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130917624 CMS
ABBVIE INC. $3,750.0004/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103150471 CMS
ABBVIE INC. $5,250.0003/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103150469 CMS
ABBVIE INC. $120.7503/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744237 CMS
Janssen Scientific Affairs, LLC $9,000.0003/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858390 CMS
Janssen Scientific Affairs, LLC $53.9703/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858398 CMS
Janssen Scientific Affairs, LLC $35.9903/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858412 CMS
Janssen Scientific Affairs, LLC $35.4403/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858428 CMS
Janssen Scientific Affairs, LLC $180.0603/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858438 CMS
ABBVIE INC. $303.5903/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104185692 CMS
ABBVIE INC. $591.1003/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104185694 CMS
Janssen Scientific Affairs, LLC $231.5603/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858362 CMS
Janssen Scientific Affairs, LLC $149.9703/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858400 CMS
Janssen Scientific Affairs, LLC $1,226.1603/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078858456 CMS
ABBVIE INC. $87.8003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744235 CMS
ABBVIE INC. $28.9502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744233 CMS
ABBVIE INC. $19.1002/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744231 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,340.8302/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137549640 CMS
ABBVIE INC. $5.9102/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744229 CMS
Janssen Biotech, Inc. $5,250.0001/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624845 CMS
Janssen Biotech, Inc. $5,250.0001/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078625076 CMS
Janssen Biotech, Inc. $64.7401/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078625569 CMS
Takeda Pharmaceuticals U.S.A., Inc. $118.1101/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137549636 CMS
PFIZER INC. $44.1001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130916165 CMS
Janssen Biotech, Inc. $12.3901/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078626226 CMS
Janssen Biotech, Inc. $160.8801/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078626331 CMS
Janssen Biotech, Inc. $15.6001/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624838 CMS
Janssen Biotech, Inc. $123.3101/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078625418 CMS
ABBVIE INC. $18.1401/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744227 CMS
ABBVIE INC. $20.3101/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103744225 CMS
PFIZER INC. $6,700.0001/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130920486 CMS
ABBVIE INC. $2,700.0001/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103134477 CMS
ABBVIE INC. $28.7501/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104185690 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $87,266.88 122
PY2020 $20,302.82 39
PY2021 $34,958.14 71
PY2022 $126,128.60 127
PY2023 $162,131.11 175
PY2024 $164,450.85 139
PY2025 $192,796.71 104

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $363,752.37 50
PY2024 Principal investigator $141,217.02 44
PY2023 Principal investigator $199,605.21 22
PY2022 Principal investigator $236,596.85 20
PY2021 Principal investigator $153,187.10 20
PY2020 Principal investigator $94,097.08 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 12/29/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269207
Principal investigator 1 Janssen Research & Development, LLC $3,625.00 12/29/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269507
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269181
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269262
Principal investigator 1 Janssen Research & Development, LLC $3,969.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269303
Principal investigator 1 Janssen Research & Development, LLC $3,705.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269396
Principal investigator 1 Janssen Research & Development, LLC $3,178.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269404
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269515
Principal investigator 1 Janssen Research & Development, LLC $3,705.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269539
Principal investigator 1 Janssen Research & Development, LLC $3,178.00 10/27/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269606
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,835.00 08/07/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 1223267882
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 08/07/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 1223267884
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 08/07/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 1223267886
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 08/07/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 1223267888
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,712.00 08/07/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 1223267890
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196.00 08/07/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 1223267892
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,800.00 08/07/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 1223267894
Principal investigator 1 Janssen Research & Development, LLC $3,178.00 07/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269524
Principal investigator 1 Janssen Research & Development, LLC $3,178.00 07/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269591
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 06/30/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269431
Principal investigator 1 Janssen Research & Development, LLC $3,625.00 06/30/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269598
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 06/30/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269620
Principal investigator 1 Amgen Inc. $59,630.20 06/04/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY OFSOUTH CAROLINA
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1246644254
Principal investigator 1 ABBVIE INC. $784.50 06/03/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY SOUTH CAROLINA
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202488075
Principal investigator 1 ABBVIE INC. $6,557.20 05/06/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY SOUTH CAROLINA
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202481799
Principal investigator 1 Janssen Research & Development, LLC $3,705.00 04/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269162
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269221
Principal investigator 1 Janssen Research & Development, LLC $9,132.00 04/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269292
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 04/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269499
Principal investigator 1 Janssen Research & Development, LLC $3,755.00 04/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269530
Principal investigator 1 Janssen Research & Development, LLC $3,640.00 04/28/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269554
Principal investigator 1 Celgene Corporation $76,256.27 04/23/2025 Non-covered Recipient Entity
Medical University Of South Carolina
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222304695
Principal investigator 1 Janssen Research & Development, LLC $3,625.00 04/21/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269213
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 04/21/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269233
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 04/21/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269270
Principal investigator 1 Janssen Research & Development, LLC $3,625.00 04/21/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269285
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 04/21/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175269480
Principal investigator 1 Celgene Corporation $57,613.20 03/25/2025 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222304679
Principal investigator 1 Celgene Corporation $30,925.00 03/25/2025 Non-covered Recipient Entity
Medical University Of South Carolina
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222304813
Principal investigator 1 Janssen Research & Development, LLC $1,040.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269189
Principal investigator 1 Janssen Research & Development, LLC $2,464.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269197
Principal investigator 1 Janssen Research & Development, LLC $16,250.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269240
Principal investigator 1 Janssen Research & Development, LLC $1,776.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269344
Principal investigator 1 Janssen Research & Development, LLC $616.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269438
Principal investigator 1 Janssen Research & Development, LLC $3,603.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269445
Principal investigator 1 Janssen Research & Development, LLC $1,495.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269452
Principal investigator 1 Janssen Research & Development, LLC $390.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269577
Principal investigator 1 Janssen Research & Development, LLC $294.00 03/10/2025 Non-covered Recipient Entity
Medcl Univ Of S Carolina
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175269629
Principal investigator 1 ABBVIE INC. $50.00 02/05/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY SOUTH CAROLINA
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202446006
Principal investigator 1 ABBVIE INC. $50.00 01/02/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY SOUTH CAROLINA
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202435951